BibSonomy :: publication ::

tag user group author concept BibTeX key search:all search:kanefendt

The blue social bookmark and publication sharing system.

entry of kanefendt:

(0)

This publication has not been reviewed yet.

rating distribution

average user rating

The average rating is computed over all reviews. However, some of them may be invisible to you due to the visibility setting chosen by the reviewers.

(0.0 of 5.0 based on 0 reviews)

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

by: Anat Norden-Zfoni, Jayesh Desai, Judith Manola, Paul Beaudry, Jeremy Force, Robert Maki, Judah Folkman, Carlo Bello, Charles Baum, Sam E. DePrimo, David R. Shalinsky, Goerge D. Demetri, and John V. Heymach

In: Clin Cancer Res, Vol. 13, Nr. 9 (2007) , p. 2643-2650.

Resources (URL, PDF, PS...)

URL:	http://clincancerres.aacrjournals.org/cgi/content/abstract/13/9/2643

Purpose: There is an unmet need for noninvasive markers to measure the biological effects of targeted agents, particularly those inhibiting the vascular endothelial growth factor VEGF receptor VEGFR pathway, and identify patients most likely to benefit from treatment. In this study, we investigated potential blood-based biomarkers for SU11248 sunitinib malate, a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors. Experimental Design: Patients n = 73 enrolled in a phase I/II trial received SU11248 daily for 14 or 28 days followed by 14 days without treatment per cycle. Clinical benefit was defined as progression-free survival of >6 months. We assessed plasma markers, including VEGF and soluble VEGFR-2 sVEGFR-2, and two cellular populations bearing VEGF receptors: monocytes and, in a subset of patients, mature circulating endothelial cells CEC. Results: Compared to patients with progressive disease, patient

BibTeX record

@article{NordenZfoni.2007,
  abstract = {Purpose: There is an unmet need for noninvasive markers to measure the biological effects of targeted agents, particularly those inhibiting the vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway, and identify patients most likely to benefit from treatment. In this study, we investigated potential blood-based biomarkers for SU11248 (sunitinib malate), a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors. Experimental Design: Patients (n = 73) enrolled in a phase I/II trial received SU11248 daily for 14 or 28 days followed by 14 days without treatment per cycle. Clinical benefit was defined as progression-free survival of >6 months. We assessed plasma markers, including VEGF and soluble VEGFR-2 (sVEGFR-2), and two cellular populations bearing VEGF receptors: monocytes and, in a subset of patients, mature circulating endothelial cells (CEC). Results: Compared to patients with progressive disease, patient},
  added-at = {2010-02-05T11:28:39.000+0100},
  author = {Norden-Zfoni, Anat and Desai, Jayesh and Manola, Judith and Beaudry, Paul and Force, Jeremy and Maki, Robert and Folkman, Judah and Bello, Carlo and Baum, Charles and DePrimo, Sam E. and Shalinsky, David R. and Demetri, Goerge D. and Heymach, John V.},
  biburl = {http://www.bibsonomy.org/bibtex/2f8621c86345a8b8fe2693fc3e8855cee/kanefendt},
  interhash = {790f5c227058d8c1212c88fac303dad2},
  intrahash = {f8621c86345a8b8fe2693fc3e8855cee},
  journal = {Clin Cancer Res},
  keywords = {Cells Endothelial Monocytes Population SU11248 Tyrosine cells identify},
  number = 9,
  pages = {2643-2650},
  timestamp = {2010-02-05T11:28:39.000+0100},
  title = {Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor},
  url = {http://clincancerres.aacrjournals.org/cgi/content/abstract/13/9/2643},
  volume = 13,
  year = 2007
}

Endnote record

%0 Journal Article
%1 NordenZfoni.2007
%A Norden-Zfoni, Anat
%A Desai, Jayesh
%A Manola, Judith
%A Beaudry, Paul
%A Force, Jeremy
%A Maki, Robert
%A Folkman, Judah
%A Bello, Carlo
%A Baum, Charles
%A DePrimo, Sam E.
%A Shalinsky, David R.
%A Demetri, Goerge D.
%A Heymach, John V.
%D 2007
%J Clin Cancer Res
%K 
%N 9
%P 2643-2650
%T Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
%U http://clincancerres.aacrjournals.org/cgi/content/abstract/13/9/2643
%V 13
%X Purpose: There is an unmet need for noninvasive markers to measure the biological effects of targeted agents, particularly those inhibiting the vascular endothelial growth factor (VEGF) receptor (VEGFR) pathway, and identify patients most likely to benefit from treatment. In this study, we investigated potential blood-based biomarkers for SU11248 (sunitinib malate), a multitargeted tyrosine kinase inhibitor, in patients with metastatic imatinib-refractory gastrointestinal stromal tumors. Experimental Design: Patients (n = 73) enrolled in a phase I/II trial received SU11248 daily for 14 or 28 days followed by 14 days without treatment per cycle. Clinical benefit was defined as progression-free survival of >6 months. We assessed plasma markers, including VEGF and soluble VEGFR-2 (sVEGFR-2), and two cellular populations bearing VEGF receptors: monocytes and, in a subset of patients, mature circulating endothelial cells (CEC). Results: Compared to patients with progressive disease, patient

BibSonomy :: publication ::

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

Resources (URL, PDF, PS...)

Abstract

BibTeX record

Endnote record